ABBV-291
- Generic Name
- ABBV-291
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 165
- Registration Number
- NCT06667687
- Locations
- 🇺🇸
Carolina BioOncology Institute /ID# 265259, Huntersville, North Carolina, United States
🇺🇸Willamette Valley Cancer Institute and Research Center /ID# 270945, Eugene, Oregon, United States
🇺🇸Texas Oncology - Central/South Texas /ID# 270946, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath